Cytokinetics (CYTK) Restructuring Costs (2012)

Cytokinetics (CYTK) posted quarterly Restructuring Costs of -$2000.0 for Q3 2012, up 84.62% quarter-over-quarter from -$13000.0 in Q2 2012.

Cytokinetics (CYTK) Restructuring Costs (2012) Analysis & Trends

Cytokinetics (CYTK) has reported Restructuring Costs for 1 consecutive years, with -$2000.0 the latest figure, recorded in Q3 2012.

In Q3 2012, Restructuring Costs changed N/A year-over-year to -$2000.0; the TTM figure through Dec 2012 stood at -$56000.0 (changed N/A YoY), while the FY2012 annual figure was -$56000.0, down 104.7% from the prior year.
Restructuring Costs grew to -$2000.0 in Q3 2012 per CYTK's latest filing, from -$13000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at -$2000.0 in Q3 2012 and bottomed at -$41000.0 in Q1 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Cytokinetics	10.31 Bn	9.14 Bn	25.89 Mn

Download Data